These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 6312995)

  • 1. Reaction of the antithrombotic and antimetastatic agent, nafazatrom, with oxidizing radicals.
    Sevilla MD; Neta P; Marnett LJ
    Biochem Biophys Res Commun; 1983 Sep; 115(3):800-6. PubMed ID: 6312995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom.
    Marnett LJ; Siedlik PH; Ochs RC; Pagels WR; Das M; Honn KV; Warnock RH; Tainer BE; Eling TE
    Mol Pharmacol; 1984 Sep; 26(2):328-35. PubMed ID: 6434940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reaction kinetics of alpha-tocopheroxyl radical with biologically and pharmacologically active substances.
    Ondrias K; Misík V; Brezová V; Stasko A
    Free Radic Res Commun; 1993; 19(1):17-28. PubMed ID: 8225031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nafazatrom (Bay g-6575), an antithrombotic and antimetastatic agent, inhibits 15-hydroxyprostaglandin dehydrogenase.
    Wong PY; Chao PH; McGiff JC
    J Pharmacol Exp Ther; 1982 Dec; 223(3):757-60. PubMed ID: 6754908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nafazatrom inhibits peroxidation of phosphatidylcholine liposomes, heart homogenate and low density lipoproteins.
    Ondrias K; Stasko A; Gergèl D; Ondriasovà E; Hromadová M
    Gen Physiol Biophys; 1997 Jun; 16(2):151-62. PubMed ID: 9437256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidant paradoxes of phenolic compounds: peroxyl radical scavenger and lipid antioxidant, etoposide (VP-16), inhibits sarcoplasmic reticulum Ca(2+)-ATPase via thiol oxidation by its phenoxyl radical.
    Ritov VB; Goldman R; Stoyanovsky DA; Menshikova EV; Kagan VE
    Arch Biochem Biophys; 1995 Aug; 321(1):140-52. PubMed ID: 7639514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between dose, pharmacokinetics, plasma-concentrations and antithrombotic effects of nafazatrom.
    Philipp E; Ritter W; Patzschke K
    Thromb Res Suppl; 1983; 4():129-33. PubMed ID: 6579706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine.
    Massad L; Plotkine M; Boulu RG
    Thromb Res; 1988 Jun; 50(5):617-25. PubMed ID: 3137682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference with tumor cell-induced degradation of endothelial matrix on the antimetastatic action of nafazatrom.
    Maniglia CA; Loulakis PP; Sartorelli AC
    J Natl Cancer Inst; 1986 Apr; 76(4):739-44. PubMed ID: 3457206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective actions of nafazatrom in traumatic shock.
    Lefer AM; Messenger M
    Arzneimittelforschung; 1982; 32(9):1089-91. PubMed ID: 6890831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redox reactions of tocopherol monoglucoside in aqueous solutions: a pulse radiolysis study.
    Kapoor S; Mukherjee T; Kagiya TV; Nair CK
    J Radiat Res; 2002 Mar; 43(1):99-106. PubMed ID: 12056334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical study of a new antimetastatic compound, Nafazatrom (Bay g 6575). Effects on platelet consumption and monocyte prostaglandin production in patients with advanced cancer.
    Warrell RP; Bockman RS; Staszewski H; Maiese K
    Cancer; 1986 Apr; 57(8):1455-60. PubMed ID: 2936443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct evidence for recycling of myeloperoxidase-catalyzed phenoxyl radicals of a vitamin E homologue, 2,2,5,7,8-pentamethyl-6-hydroxy chromane, by ascorbate/dihydrolipoate in living HL-60 cells.
    Kagan VE; Kuzmenko AI; Shvedova AA; Kisin ER; Li R; Martin I; Quinn PJ; Tyurin VA; Tyurina YY; Yalowich JC
    Biochim Biophys Acta; 2003 Mar; 1620(1-3):72-84. PubMed ID: 12595076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase.
    Kagan VE; Kuzmenko AI; Tyurina YY; Shvedova AA; Matsura T; Yalowich JC
    Cancer Res; 2001 Nov; 61(21):7777-84. PubMed ID: 11691792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin E analogue Trolox C. E.s.r. and pulse-radiolysis studies of free-radical reactions.
    Davies MJ; Forni LG; Willson RL
    Biochem J; 1988 Oct; 255(2):513-22. PubMed ID: 2849418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First use of nafazatrom, a new antithrombotic drug, in pregnancy.
    Elder MG; Myatt L
    Lancet; 1984 Jun; 1(8390):1350. PubMed ID: 6145042
    [No Abstract]   [Full Text] [Related]  

  • 17. A time-resolved electron spin resonance study of the oxidation of ascorbic acid by hydroxyl radical.
    Fessenden RW; Verma NC
    Biophys J; 1978 Oct; 24(1):93-101. PubMed ID: 213133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nafazatrom (BAY g 6575), a potent stimulator of prostacyclin release from cardiac and renal vessel wall.
    Klitzke AK
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):220-8. PubMed ID: 6391401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidant properties of natural and synthetic chromanol derivatives: study by fast kinetics and electron spin resonance spectroscopy.
    Gregor W; Grabner G; Adelwöhrer C; Rosenau T; Gille L
    J Org Chem; 2005 Apr; 70(9):3472-83. PubMed ID: 15844980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of nafazatrom in body fluids by high-performance thin-layer chromatography with post-chromatographic derivatization.
    Ritter W
    J Chromatogr; 1984 May; 290():97-105. PubMed ID: 6736168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.